| Reference number | |
|------------------|--|
| 1790-H | |

SPECIALTY QUANTITY LIMIT PROGRAM

CAPRELSA (vandetanib)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for the treatment of medullary thyroid cancer, follicular, Hurthle, and papillary thyroid cancer, and non-small cell lung cancer with RET gene arrangements fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

| Medication | Standard Limit | FDA-recommended dosing |
|-------------------------|----------------|---|
| Caprelsa 100 mg tablets | 60 per 30 days | Standard dosing: 300 mg per day |
| Caprelsa 300 mg tablets | 30 per 30 days | Severe toxicities, QTc interval prolongation: 200 r (two 100 mg tablets) or 100 mg per day Renal impairment: 200 mg per day |

III. REFERENCES

1. Caprelsa [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals; December 2016.

Specialty Quantity Limit Caprelsa P2018a.docx

pharmaceutical manufacturers that are not affiliated with CVS Caremark.

© 2018 CVS Caremark. All rights reserved.



This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of